Strategies to Tap the Resources Available in China
Product Description
A best report of the same type available on the market.
The report first time described a complete and comprehensive package of strategies suitable to any sized Western pharma/biotech companies to pursue their China opportunity. It analyzed in depth both the advantages and disadvantages of each of these strategies. Furthermore, it provided useful strategies to these companies of how to overcome challenges when entering Chinese market.
The report illustrated these strategies with case studies of abundant real examples. It also described in detail the activities of 66 Western companies currently pursuing opportunities in China. These companies include major pharma/biopharma companies, small-sized biotech companies, multinational CROs, generic drug makers, as well as venture capital investors.
In addition, the report includes detailed information of 48 best Chinese companies in the areas of traditional pharmaceutical, biotechnology, contract pharmaceutical research, and contract pharmaceutical manufacturing, including their capabilities in R&D and/or manufacturing.
Accessories